Unique ID issued by UMIN | UMIN000012693 |
---|---|
Receipt number | R000014832 |
Scientific Title | Comparison of gastric and small-bowel transit time between lubiprostone and placebo in healthy volunteers: a double-blind, placebo-controlled study by capsule endoscopy |
Date of disclosure of the study information | 2013/12/27 |
Last modified on | 2014/01/16 16:26:36 |
Comparison of gastric and small-bowel transit time between lubiprostone and placebo in healthy volunteers: a double-blind, placebo-controlled study by capsule endoscopy
Comparison of gastric and small-bowel transit time between lubiprostone and placebo: a double-blind, placebo-controlled study by capsule endoscopy
Comparison of gastric and small-bowel transit time between lubiprostone and placebo in healthy volunteers: a double-blind, placebo-controlled study by capsule endoscopy
Comparison of gastric and small-bowel transit time between lubiprostone and placebo: a double-blind, placebo-controlled study by capsule endoscopy
Japan |
Healthy volunteers
Gastroenterology |
Others
NO
Lubiprostone, a selective activator of type 2 chloride channels, is approved for treatment of chronic idiopathic constipation and recently constipation-predominant irritable bowel syndrome. It has been suggested that lubiprostone has a prokinetic effect.
We study that comparison of gastric and small-bowel transit time between Lubiprostone, and placebo-controlled in healthy volunteers : a double-blind, placebo-controlled study by capsule endoscopy
Others
gastric empting time, small bowel transit time
Exploratory
Pragmatic
Not applicable
gastric and small-bowel transit time
Endoscopic image
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Active
NO
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
The group who takes lubiprostone 24µg
The group who takes Placebo
20 | years-old | <= |
Not applicable |
Male and Female
Patient who fills everything the following
1) Patient of 20 years or more
2) Patient who gives written informed consent
The patient who collides with either the following assumes that it dosen't put it in to the examination
1) Drug allergy
2) Subjects with malignancy
3) Others
20
1st name | |
Middle name | |
Last name | Masahiko Inamori |
Yokohama City University Hospital
Office of postgraduate medical education
3-9 Fuku-ura, Kanagawa-ku, Yokohama, Japan
+81-45-787-2800
inamorim@med.yokohama-cu.ac.jp
1st name | |
Middle name | |
Last name | Masahiko Inamori |
Yokohama City University Hospital
Office of postgraduate medical education
3-9 Fuku-ura, Kanagawa-ku, Yokohama, Japan
+81-45-787-2800
inamorim@med.yokohama-cu.ac.jp
Office of postgraduate medical education, Yokohama City University Hospital
ABBOTT JAPAN CO. LTD
Profit organization
Japan
NO
横浜市立大学附属病院(神奈川県)
2013 | Year | 12 | Month | 27 | Day |
Unpublished
Open public recruiting
2013 | Year | 11 | Month | 01 | Day |
2014 | Year | 01 | Month | 06 | Day |
2013 | Year | 12 | Month | 25 | Day |
2014 | Year | 01 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014832
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |